ENZN:OTC-Enzon Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | OTC

Last Closing Price

USD 0.50

Change

+0.00 (+0.40)%

Market Cap

USD 0.04B

Volume

0.14M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Enzon Pharmaceuticals, Inc., together with its subsidiaries, licenses drug products. Its marketed drug products include PegIntron and Sylatron. The company was incorporated in 1981 and is headquartered in Cranford, New Jersey.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-08-03 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF Novo Nordisk A/S

+0.05 (+0.05%)

USD212.61B 31.19 3.55
CMXHF CSL Limited

+2.88 (+1.34%)

USD97.25B 36.29 29.67
CSLLY CSL Limited

+1.16 (+1.07%)

USD97.25B 36.40 29.67
GNMSF Genmab A/S

+16.28 (+3.62%)

USD29.68B 33.54 3.84
UCBJY UCB SA

-0.04 (-0.07%)

USD20.83B 19.10 14.66
UCBJF UCB SA

N/A

USD20.47B 18.27 14.66
SBHMY Sino Biopharmaceutical Limited

N/A

USD16.03B 27.42 2.24
SBMFF Sino Biopharmaceutical Limited

N/A

USD16.02B 26.45 2.24
AKBLF ALK-Abelló A/S

N/A

USD5.40B 507.82 13.29
AKABY ALK-Abelló A/S

N/A

USD5.40B 495.31 13.46

ETFs Containing ENZN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 99.80% 82% B- 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 99.80% 82% B- 82% B-
Trailing 12 Months  
Capital Gain 162.89% 84% B 82% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 162.89% 84% B 82% B-
Trailing 5 Years  
Capital Gain 27.75% 64% D 52% F
Dividend Return 107.42% 100% A+ 96% A
Total Return 135.17% 77% C+ 73% C
Average Annual (5 Year Horizon)  
Capital Gain 21.85% 44% F 60% D-
Dividend Return 27.49% 100% A+ 86% B
Total Return 48.97% 59% F 71% C-
Risk Return Profile  
Volatility (Standard Deviation) 88.41% 51% F 36% F
Risk Adjusted Return 55.39% 85% B 81% B-
Market Capitalization 0.04B 61% D- 44% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 1.57 79% C+ 91% A-
Price/Book Ratio 5.46 52% F 24% F
Price / Cash Flow Ratio -105.40 94% A 94% A
EV/EBITDA 10.16 52% F 35% F
Management Effectiveness  
Return on Equity -3.95% 79% C+ 39% F
Return on Invested Capital -4.87% 51% F 31% F
Return on Assets -2.42% 86% B 43% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.71 58% F 35% F
Short Percent 0.86% 64% D 40% F
Beta 0.35 69% D+ 73% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector